Logo image of SAVA

CASSAVA SCIENCES INC (SAVA) Stock Fundamental Analysis

USA - NASDAQ:SAVA - US14817C1071 - Common Stock

3.03 USD
+0.07 (+2.36%)
Last: 11/10/2025, 7:09:57 PM
2.97 USD
-0.06 (-1.98%)
After Hours: 11/10/2025, 7:09:57 PM
Fundamental Rating

2

Overall SAVA gets a fundamental rating of 2 out of 10. We evaluated SAVA against 191 industry peers in the Pharmaceuticals industry. SAVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SAVA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SAVA had negative earnings in the past year.
In the past year SAVA has reported a negative cash flow from operations.
SAVA had negative earnings in each of the past 5 years.
In the past 5 years SAVA always reported negative operating cash flow.
SAVA Yearly Net Income VS EBIT VS OCF VS FCFSAVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

SAVA has a worse Return On Assets (-90.98%) than 75.92% of its industry peers.
SAVA has a Return On Equity of -140.01%. This is in the lower half of the industry: SAVA underperforms 67.02% of its industry peers.
Industry RankSector Rank
ROA -90.98%
ROE -140.01%
ROIC N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
SAVA Yearly ROA, ROE, ROICSAVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SAVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SAVA Yearly Profit, Operating, Gross MarginsSAVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

SAVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SAVA has more shares outstanding
SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SAVA Yearly Shares OutstandingSAVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SAVA Yearly Total Debt VS Total AssetsSAVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

SAVA has an Altman-Z score of -5.65. This is a bad value and indicates that SAVA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.65, SAVA is not doing good in the industry: 61.26% of the companies in the same industry are doing better.
SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.65
ROIC/WACCN/A
WACCN/A
SAVA Yearly LT Debt VS Equity VS FCFSAVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

SAVA has a Current Ratio of 2.43. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.43, SAVA perfoms like the industry average, outperforming 45.03% of the companies in the same industry.
A Quick Ratio of 2.43 indicates that SAVA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.43, SAVA is in line with its industry, outperforming 50.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.43
SAVA Yearly Current Assets VS Current LiabilitesSAVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

SAVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.50%, which is quite impressive.
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-787.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SAVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 102.72% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-35.77%
EPS Next 2Y8.81%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SAVA Yearly EPS VS EstimatesSAVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SAVA. In the last year negative earnings were reported.
Also next year SAVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAVA Price Earnings VS Forward Price EarningsSAVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAVA Per share dataSAVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

SAVA's earnings are expected to grow with 102.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.81%
EPS Next 3Y102.72%

More info and screens

0

5. Dividend

5.1 Amount

SAVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CASSAVA SCIENCES INC

NASDAQ:SAVA (11/10/2025, 7:09:57 PM)

After market: 2.97 -0.06 (-1.98%)

3.03

+0.07 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05
Earnings (Next)03-02 2026-03-02/amc
Inst Owners25.22%
Inst Owner Change-1.17%
Ins Owners5.73%
Ins Owner Change0.76%
Market Cap146.38M
Revenue(TTM)N/A
Net Income(TTM)-123.17M
Analysts80
Price Target5.1 (68.32%)
Short Float %16.25%
Short Ratio2.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)150%
PT rev (3m)150%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-250.91%
EPS NY rev (3m)-250.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -90.98%
ROE -140.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.43
Altman-Z -5.65
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.28%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-787.31%
EPS Next Y-35.77%
EPS Next 2Y8.81%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.94%
OCF growth 3YN/A
OCF growth 5YN/A

CASSAVA SCIENCES INC / SAVA FAQ

What is the ChartMill fundamental rating of CASSAVA SCIENCES INC (SAVA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SAVA.


Can you provide the valuation status for CASSAVA SCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to CASSAVA SCIENCES INC (SAVA). This can be considered as Overvalued.


What is the profitability of SAVA stock?

CASSAVA SCIENCES INC (SAVA) has a profitability rating of 0 / 10.


How financially healthy is CASSAVA SCIENCES INC?

The financial health rating of CASSAVA SCIENCES INC (SAVA) is 6 / 10.


Can you provide the expected EPS growth for SAVA stock?

The Earnings per Share (EPS) of CASSAVA SCIENCES INC (SAVA) is expected to decline by -35.77% in the next year.